Quell

AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

Retrieved on: 
Tuesday, February 6, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240206590080/en/
    New AstraZeneca facility in Rockville, Maryland (Photo: Business Wire)
    The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics , AbelZeta, Cellectis , and the acquisition of Neogene Therapeutics.
  • In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics, harnessing leading pharmaceutical technology and development.
  • AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune system’s T-cells to more effectively fight cancer.
  • Beyond this, the company is advancing a pipeline of novel T-cell receptor therapies (TCR-Ts) through Neogene Therapeutics, a wholly owned subsidiary of AstraZeneca.

2024 RC Show Competitions LEVEL UP and Heat Up!

Retrieved on: 
Thursday, February 1, 2024

-- 30 --

Key Points: 
  • Do you think you have what it takes to lead the pack and ‘LEVEL UP’ the industry?
  • RC Show 2024 is ready to shine a spotlight on the nation’s very best and brightest talent.
  • From how to discover new flavours, reimagine classics, and surpass diner's experiences, LEVEL UP is all about helping industry professionals take their craft and business to the next level.
  • Don't miss out on this unparalleled opportunity to see this year’s competitors showcase their hospitality game while they LEVEL UP April 8-10 at RC Show 2024!

The Cannabist Company Adds Successful California House of Brands, Ciencia Labs, to its National Portfolio

Retrieved on: 
Thursday, February 1, 2024

“The Ciencia Labs team has created one of the most interesting and innovative product portfolios in cannabis, and their brands’ impressive reach in California speaks to their creativity and passion for product development,” said Jesse Channon, President, The Cannabist Company.

Key Points: 
  • “The Ciencia Labs team has created one of the most interesting and innovative product portfolios in cannabis, and their brands’ impressive reach in California speaks to their creativity and passion for product development,” said Jesse Channon, President, The Cannabist Company.
  • As the founders of a bootstrapped start-up, this is a very exciting outcome for us,” said Benjamin Mitchell, Ciencia Labs Co-Founder and CEO.
  • I also look forward to supporting The Cannabist Company team as they continue the development of these brands and take them to new markets,” adds Carolina Vazquez Mitchell, Ciencia Labs Co-Founder and Chief Scientific Officer.
  • The team at The Cannabist Company shares our same passion for differentiated and industry-changing marketing and sales approaches, and I am incredibly excited to be joining The Cannabist Company to support their wholesale efforts for their entire portfolio of brands, including those from Ciencia Labs.

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

Retrieved on: 
Tuesday, December 12, 2023

The trial was conducted at the Baylor College of Medicine in collaboration with C2SHIP.

Key Points: 
  • The trial was conducted at the Baylor College of Medicine in collaboration with C2SHIP.
  • The principal investigator was Dr. Bijan Najafi, Professor of Surgery, and clinical director at the Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine.
  • According to the Centers for Disease Control and Prevention (CDC), about 10 million Americans have PACS.
  • "This pilot trial suggests that Quell may alleviate fibromyalgia-like pain and other symptoms of Long Covid.

Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer

Retrieved on: 
Tuesday, December 12, 2023

Bernd Schmidt previously worked at Quell Therapeutics where he served as Vice President Product Delivery.

Key Points: 
  • Bernd Schmidt previously worked at Quell Therapeutics where he served as Vice President Product Delivery.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “I am thrilled to welcome Bernd Schmidt to Sensorion as our new CTO.
  • I would like to congratulate Bernd in his new role and welcome in our team.”
    Bernd Schmidt, Chief Technical Officer of Sensorion, commented: “I am looking forward to joining a company with such a pioneering and visionary approach in the complex gene therapy field.
  • Sensorion wishes David well in his retirement and thanks him for his contribution.

NeuroMetrix Reports Q3 2023 Business Highlights

Retrieved on: 
Thursday, October 26, 2023

WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023.

Key Points: 
  • WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023.
  • Financial results in Q3 2023 were consistent with Company expectations and reflect the substantial changes to Medicare Advantage risk-adjustment reimbursement implemented by CMS in Q1 2023.
  • Revenue in Q3 2023 of $1.2 million was lower by $0.8 million or 39% from Q3 2022 primarily due to reduced sales volume for DPNCheck.
  • The Q3 2023 net loss was $1.8 million ($0.21 per share) versus a net loss of $1.6 million ($0.23 per share) in Q3 2022.

GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies

Retrieved on: 
Wednesday, September 27, 2023

The Company’s genomically recoded organism (GRO) platform enables precise placement of non-standard amino acids (NSAAs) within a protein to realize previously unattainable therapeutic capabilities.

Key Points: 
  • The Company’s genomically recoded organism (GRO) platform enables precise placement of non-standard amino acids (NSAAs) within a protein to realize previously unattainable therapeutic capabilities.
  • ProGly NSAAs contain glycans that can elicit a defined immune response to the underlying protein.
  • Each ProGly NSAA carries a glycan-based tolerance signal that reeducates the immune system to recognize the underlying protein as “self” rather than “foreign”.
  • The Company presented data showing that ProGly produced a profound improvement in experimental autoimmune myasthenia gravis, a highly translatable animal model of MG.

NeuroMetrix Reports Q2 2023 Business Highlights

Retrieved on: 
Thursday, July 27, 2023

WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023.

Key Points: 
  • WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023.
  • Revenue in Q2 2023 of $1.7 million was lower by $0.5 million or 23% from Q2 2022 primarily due to reduced sales volume for DPNCheck in the Medicare Advantage market.
  • The gross margin rate of 68% in Q2 2023 was flat with Q2 2022.
  • The Q2 2023 net loss was $1.5 million ($0.19 per share) versus a net loss of $1.2 million ($0.17 per share) in Q2 2022.

Celebrated Game Designer Stieg Hedlund Joins Fitness Gaming Pioneer Quell

Retrieved on: 
Wednesday, June 28, 2023

Hedlund is well known for having invented dozens of now-standard game mechanics, and brings his expertise of game design innovation to Quell as the company works to revolutionise the burgeoning fitness gaming sector.

Key Points: 
  • Hedlund is well known for having invented dozens of now-standard game mechanics, and brings his expertise of game design innovation to Quell as the company works to revolutionise the burgeoning fitness gaming sector.
  • The Quell Impact is available to pre-order at: www.playquell.com
    Pre-order customers currently receive a complimentary one-year Quell subscription which includes the full suite of Quell games, fitness analytics and adaptive coaching.
  • Stieg Hedlund commented: “I love the design philosophy of Quell: using the fun and immersion of gaming to drive positive effects on people’s mental and physical wellbeing.
  • I’m delighted to be working with Quell to open a new chapter for the gaming industry.”
    Cameron Brookhouse, CEO of Quell, commented: “We’re thrilled to welcome Stieg to Team Quell.

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

Retrieved on: 
Friday, June 9, 2023

“We are extremely pleased to have AstraZeneca on board as our first major partner.

Key Points: 
  • “We are extremely pleased to have AstraZeneca on board as our first major partner.
  • This collaboration builds on our pioneering work to develop exquisitely engineered, multi-modular Treg cell therapies for immune disorders and provides excellent validation for the technologies and capabilities we have established,” said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • Quell will receive $85 million upfront from AstraZeneca, which comprises a predominant cash payment and an equity investment.
  • Quell is also eligible to receive over $2 billion for further development and commercialization milestones, if successful, plus tiered royalties.